A technical comparison of spatial transcriptomics platforms across six cancer types


Por: Cervilla, S, Grases, D, Perez, E, Real, FX, Musulen, E, Aprea, J, Esteller, M and Porta-Pardo, E

Publicada: 12 ene 2026
Resumen:
BackgroundSpatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology.ResultsHere, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance.ConclusionsCollectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors.

Filiaciones:
:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

Real, FX:
 Ctr Nacl Invest Oncol CNIO, Madrid, Spain

 Ctr Invest Biomed Red CIBERONC, Madrid, Spain

 Univ Pompeu Fabra, Dept Med & Ciencies Vida, Barcelona, Spain

:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

 Hosp Univ Gen Catalunya, Dept Pathol, Grp Quironsalud, Sant Cugat Del Valles, Spain

Aprea, J:
 TUD Dresden Univ Technol, DRESDEN Concept Genome Ctr, Technol Platform, Dresden, Germany

:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

 Ctr Invest Biomed Red CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

 Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain

:
 Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain

 Barcelona Supercomp Ctr BSC, Barcelona, Spain
ISSN: 1474760X





GENOME BIOLOGY
Editorial
BMC, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 27 Número: 1
Páginas:
WOS Id: 001685261600002
ID de PubMed: 41526977
imagen Green Submitted, gold

MÉTRICAS